文献速递造血干细胞移植与细胞治疗

儿童异基因造血细胞移植受者的重症监护风险与长期结局

Intensive care risk and long-term outcomes in pediatric allogeneic hematopoietic cell transplant recipients.
PubMed 文献 · Blood Adv · 2024-01-01

该研究合并国际血液与骨髓移植研究中心和虚拟儿科系统数据库,纳入2008至2014年间在美国或加拿大69个中心接受首次异基因造血细胞移植的6995例≤21岁儿童患者,随访至2020年。移植后5年内15.3%需入住ICU,ICU转出存活率85.7%,但ICU存活者中超过半数需再次入ICU,转出后1年和5年生存率分别为52.5%和42.6%。

要点

  • 移植后100天、1年、5年ICU入住率分别为8.3%、12.8%、15.3%。
  • ICU转出存活率85.7%,转出后1年和5年生存率分别为52.5%和42.6%。
  • 1年内需ICU的1年移植存活者5年生存率低10%,新发透析依赖肾衰竭比例更高(P<.001)。

核心结论

  • ICU管理常见且转出存活率高,但持续并发症导致反复ICU入住,并使部分高危患者1年结局不佳。

研究设计与样本

  • 合并国际血液与骨髓移植研究中心和虚拟儿科系统数据库的队列研究,纳入2008至2014年间在美国或加拿大69个中心接受首次异基因造血细胞移植的6995例≤21岁儿童患者,随访至2020年。

主要发现

  • 1067例患者需入住ICU(移植后100天8.3%、1年12.8%、5年15.3%),与人口学背景、移植前器官毒性、移植物类型及HLA匹配、移植物抗宿主病或恶性肿瘤复发相关。
  • ICU转出存活率为85.7%,但超过半数ICU存活者需再次入住ICU,转出后1年和5年生存率分别为52.5%和42.6%。
  • 恶性肿瘤、移植前器官功能差和同种免疫反应风险因素患者的ICU生存更差。
  • 1年内需ICU的1年移植存活者5年生存率低10%,新发透析依赖肾衰竭比例更高(P<.001)。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic hematopoietic cell transplantation (HCT) can be complicated by life-threatening organ toxicity and infection necessitating intensive care. Epidemiologic data have been limited by single-center studies, poor database granularity, and a lack of long-term survivors. To identify contemporary trends in intensive care unit (ICU) use and long-term outcomes, we merged data from the Center for International Blood and Marrow Transplant Research and the Virtual Pediatric Systems databases. We identified 6995 pediatric patients with HCT aged ≤21 years who underwent first allogeneic HCT between 2008 and 2014 across 69 centers in the United States or Canada and followed patients until the year 2020. ICU admission was required for 1067 patients (8.3% by day +100, 12.8% by 1 year, and 15.3% by 5 years after HCT), and was linked to demographic background, pretransplant organ toxicity, allograft type and HLA-match, and the development of graft-versus-host disease or malignancy relapse. Survival to ICU discharge was 85.7%, but more than half of ICU survivors required ICU readmission, leading to 52.5% and 42.6% survival at 1- and 5-years post-ICU transfer, respectively. ICU survival was worse among patients with malignant disease, poor pretransplant organ function, and alloreactivity risk factors. Among 1-year HCT survivors, those who required ICU in the first year had 10% lower survival at 5 years and developed new dialysis-dependent renal failure at a greater rate (P<.001). Thus, although ICU management is common and survival to ICU discharge is high, ongoing complications necessitate recurrent ICU admission and lead to a poor 1-year outcome in select patients who are at high risk.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Zinter MS, Brazauskas R, Strom J, et al. Intensive care risk and long-term outcomes in pediatric allogeneic hematopoietic cell transplant recipients. Blood Adv. 2024. PMID: 38127268. doi:10.1182/bloodadvances.2023011002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。